CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Urteste SA is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Urteste SA
ul. Starodworska 1
GDANSK, 80-137  Poland Ticker: URTURT
Business Summary
Urteste SA is a Poland-based company mainly engaged in the biotechnology sector. The Company operates in the field of medical devices for in vitro application in the field of cancer diagnostics. The technology developed by the Company involves the detection of cancer by measuring the activity of enzymes in a urine sample, using diagnostic tests that enable the detection of common cancers in their early stages. The Company offers tests for the detection of cancers such as, pancreatic cancer, prostate cancer, colorectal cancer, lung cancer, kidney cancer, liver cancer, biliary tract cancer, stomach cancer, esophageal cancer, ovarian cancer, endometrial cancer, breast cancer, leukemia, lymphoma, glioma.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2835 In vitro and in vivo diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President of the Management Board GrzegorzStefanski
Vice President of the Management Board TomaszKostuch
Member of the Supervisory Board GrzegorzBasak 6/29/2022 6/29/2022
4 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 1,409,669 (As of 6/30/2024)
Stock Exchange: WAR


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024